share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K：重大事件
美股sec公告 ·  05/23 16:28
Moomoo AI 已提取核心訊息
Exicure, Inc., a biotechnology company, has received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department due to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company failed to file its annual report (Form 10-K) for the year ended December 31, 2023, by the extended deadline of May 20, 2024, and also did not file its quarterly report (Form 10-Q) for the first quarter of 2024. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders. As a result, Nasdaq plans to suspend trading of Exicure's common stock at the opening of business on May 30, 2024, unless the company files an appeal by May 28, 2024. Exicure intends to appeal the delisting and request a stay of suspension while it works to regain compliance. The company is actively working to complete and file the overdue reports and to hold a combined Annual Meeting for 2023 and 2024 as soon as possible. However, there is no assurance that Exicure will be able to regain compliance or be successful in its appeal to Nasdaq.
Exicure, Inc., a biotechnology company, has received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department due to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company failed to file its annual report (Form 10-K) for the year ended December 31, 2023, by the extended deadline of May 20, 2024, and also did not file its quarterly report (Form 10-Q) for the first quarter of 2024. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders. As a result, Nasdaq plans to suspend trading of Exicure's common stock at the opening of business on May 30, 2024, unless the company files an appeal by May 28, 2024. Exicure intends to appeal the delisting and request a stay of suspension while it works to regain compliance. The company is actively working to complete and file the overdue reports and to hold a combined Annual Meeting for 2023 and 2024 as soon as possible. However, there is no assurance that Exicure will be able to regain compliance or be successful in its appeal to Nasdaq.
生物技術公司Exicure, Inc. 因未遵守納斯達克上市規則5250 (c) (1)，已收到納斯達克上市資格部門的員工退市決定。該公司未能在延長的截止日期（2024年5月20日）之前提交截至2023年12月31日止年度的年度報告（10-K表格），也沒有提交2024年第一季度的季度報告（10-Q表格）。此外，Exicure尚未舉行其2023年年度股東大會。因此，納斯達克計劃在2024年5月30日開業時暫停Exicure普通股的交易，除非該公司在2024年5月28日之前提出上訴。Exicure打算對除名提出上訴，並要求在努力恢復合規的同時暫緩停牌。該公司正在積極努力完成和提交逾期報告，並儘快舉行2023年和2024年的合併年會。但是，無法保證Exicure能夠恢復合規性或成功向納斯達克提出上訴。
生物技術公司Exicure, Inc. 因未遵守納斯達克上市規則5250 (c) (1)，已收到納斯達克上市資格部門的員工退市決定。該公司未能在延長的截止日期（2024年5月20日）之前提交截至2023年12月31日止年度的年度報告（10-K表格），也沒有提交2024年第一季度的季度報告（10-Q表格）。此外，Exicure尚未舉行其2023年年度股東大會。因此，納斯達克計劃在2024年5月30日開業時暫停Exicure普通股的交易，除非該公司在2024年5月28日之前提出上訴。Exicure打算對除名提出上訴，並要求在努力恢復合規的同時暫緩停牌。該公司正在積極努力完成和提交逾期報告，並儘快舉行2023年和2024年的合併年會。但是，無法保證Exicure能夠恢復合規性或成功向納斯達克提出上訴。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息